User login
Key clinical point: Nomograms to predict survival and prostate-specific antigen (PSA) response in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving lutetium-177 prostate-specific membrane antigen (¹⁷⁷Lu-PSMA) radionuclide treatment have been developed and externally validated.
Major finding: The median follow-up was 21.5 months. The concordance index of the overall survival model was 0.71 and PSA-progression-free survival model was 0.70. The model for PSA decline of 50% or more had a sensitivity of 94%, negative predictive value of 89%, and specificity of 38%.
Study details: Nomograms for predicting outcomes after Lu-PSMA treatment were developed (n=196) and validated (n=74) using clinical trial and real-world data of patients with late-stage mCRPC.
Disclosures: The study was supported by Prostate Cancer Foundation. The authors declared consulting, personal fees, travel fees, grants, honoraria, nonfinancial support, and patents outside this work. Dr. J Czernin reported being a founder and board member of and holding equity in Sofie Biosciences and Trethera Therapeutics.
Source: Gafita A et al. Lancet Oncol. 2021 Jul 8. doi: 10.1016/S1470-2045(21)00274-6.
Key clinical point: Nomograms to predict survival and prostate-specific antigen (PSA) response in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving lutetium-177 prostate-specific membrane antigen (¹⁷⁷Lu-PSMA) radionuclide treatment have been developed and externally validated.
Major finding: The median follow-up was 21.5 months. The concordance index of the overall survival model was 0.71 and PSA-progression-free survival model was 0.70. The model for PSA decline of 50% or more had a sensitivity of 94%, negative predictive value of 89%, and specificity of 38%.
Study details: Nomograms for predicting outcomes after Lu-PSMA treatment were developed (n=196) and validated (n=74) using clinical trial and real-world data of patients with late-stage mCRPC.
Disclosures: The study was supported by Prostate Cancer Foundation. The authors declared consulting, personal fees, travel fees, grants, honoraria, nonfinancial support, and patents outside this work. Dr. J Czernin reported being a founder and board member of and holding equity in Sofie Biosciences and Trethera Therapeutics.
Source: Gafita A et al. Lancet Oncol. 2021 Jul 8. doi: 10.1016/S1470-2045(21)00274-6.
Key clinical point: Nomograms to predict survival and prostate-specific antigen (PSA) response in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving lutetium-177 prostate-specific membrane antigen (¹⁷⁷Lu-PSMA) radionuclide treatment have been developed and externally validated.
Major finding: The median follow-up was 21.5 months. The concordance index of the overall survival model was 0.71 and PSA-progression-free survival model was 0.70. The model for PSA decline of 50% or more had a sensitivity of 94%, negative predictive value of 89%, and specificity of 38%.
Study details: Nomograms for predicting outcomes after Lu-PSMA treatment were developed (n=196) and validated (n=74) using clinical trial and real-world data of patients with late-stage mCRPC.
Disclosures: The study was supported by Prostate Cancer Foundation. The authors declared consulting, personal fees, travel fees, grants, honoraria, nonfinancial support, and patents outside this work. Dr. J Czernin reported being a founder and board member of and holding equity in Sofie Biosciences and Trethera Therapeutics.
Source: Gafita A et al. Lancet Oncol. 2021 Jul 8. doi: 10.1016/S1470-2045(21)00274-6.